1. The financial impact of hypofractionated radiation for localized prostate cancer in the United States;Moore;J Oncol,2019
2. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial;Arcangeli;J Clin Oncol,2017
3. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;Lancet Oncol,2016
4. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer;Pollack;J Clin Oncol,2013
5. Hyprofractionated versus conventionally fractionated radiotherapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multi-centre, open-label, phase 3 HYPRO trial;de Vries;Int J Radiat Oncol Biol Phys,2019